Adheris Health Limited (ASX:AHE): Can Quarterly Revenue Recovery Continue?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Adheris Health Limited (ASX:AHE): Can Quarterly Revenue Recovery Continue?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Adheris Health (ASX:AHE) traded at AUD 0.013 on 13 November 2026, unchanged.
Q1 FY27 Revenue reached AUD 6.4 million.
Quarterly Gross Profit was AUD 2.9 million at a 45.2% margin.
FY26 revenue totalled AUD 34.0 million.

Adheris Health Limited operates patient engagement programmes linking pharmaceutical companies, pharmacy networks and patients, with communications intended to support medication use and adherence. On 13 November 2026, Adheris Health (ASX:AHE) was trading at AUD 0.013, unchanged for the session. Its latest reported quarter showed improvement in revenue and gross Margin after a difficult FY26, while management continued work on programme Diversification and its commercial pipeline.

US Pharmacy Network and Patient Engagement

Adheris Health (ASX:AHE) primarily serves the United States market through relationships with pharmaceutical sponsors and pharmacy partners. Its approach uses pharmacy and longitudinal medication information to deliver targeted patient communications within pharmacy workflows. The company's THRiV platform is part of this model. Revenue depends on the scope and timing of pharmaceutical-sponsored engagement programmes rather than direct consumer sales. The Business therefore has exposure to customer budget cycles, renewal decisions and the ability to convert programme proposals into contracted activity.

September Quarter Revenue and Pipeline

In its first-quarter FY27 activities update released in October 2026, Adheris reported revenue of AUD 6.4 million, up 1.6% from the prior corresponding period and 60.5% from the preceding quarter. Gross profit reached AUD 2.9 million, increasing 8.4% year on year, while gross margin rose to 45.2%, an improvement of 2.8 percentage points. The company described a calendar-year 2027 pipeline containing more than 110 opportunities across 40 clients and 90 brands. A pipeline measures potential programmes, not booked revenue, and conversion will determine its financial contribution.

FY26 Financial Performance and Restructuring

The FY26 results presentation reported AUD 34.0 million of revenue, 46% below the preceding year. Gross profit was AUD 14.6 million and gross margin was approximately 43%, nine percentage points lower year on year. The company reported a statutory net loss of AUD 4.3 million and cash at bank of AUD 9.5 million. Underlying loss before income tax was AUD 16.7 million, a non-IFRS measure that should not be confused with the statutory result. The financial statements reflected changes to the group following the divestment of its Australia and New Zealand operations, with significant items affecting reported earnings.

Strategic Developments and Business Risks

Adheris (ASX:AHE) has been developing a broader mix of programmes as it works to reduce dependence on individual sponsor decisions. The company also reported progress toward resolving the first potential earn-out payment associated with its Australia and New Zealand business disposal. That payment remains dependent on the relevant transaction terms. Customer contract renewals, pharmaceutical Marketing budgets, programme delivery costs and technology Investment all affect the rate of any operational recovery. The company has also disclosed a disputed legal claim; its outcome cannot be inferred from the existence of the claim alone.

What to Watch Next

Further quarterly reports will indicate whether the revenue improvement recorded in the September quarter is sustained and whether gross margin remains near the reported level. Investors can also monitor programme conversions from the disclosed 2027 pipeline, receipts and costs, and developments relating to the divestment earn-out. Changes in cash balances and Operating Cash Flow are relevant because the FY26 accounts recorded an underlying loss. Any revised financial-year reporting arrangements should be read alongside the company's formal disclosure.

Key Insights

Adheris entered FY27 following a year of lower revenue and margins, but its first-quarter update recorded improved sequential trading. The business remains centred on US patient engagement programmes whose timing depends on pharmaceutical sponsors and pharmacy relationships. Pipeline conversion, cash generation and customer retention are the most direct operational indicators in future updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.